These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26733381)

  • 21. Aloperine inhibits hepatitis C virus entry into cells by disturbing internalisation from endocytosis to the membrane fusion process.
    Lv XQ; Zou LL; Tan JL; Li H; Li JR; Liu NN; Dong B; Song DQ; Peng ZG
    Eur J Pharmacol; 2020 Sep; 883():173323. PubMed ID: 32622669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.
    Anggakusuma ; Colpitts CC; Schang LM; Rachmawati H; Frentzen A; Pfaender S; Behrendt P; Brown RJ; Bankwitz D; Steinmann J; Ott M; Meuleman P; Rice CM; Ploss A; Pietschmann T; Steinmann E
    Gut; 2014 Jul; 63(7):1137-49. PubMed ID: 23903236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
    Calland N; Sahuc ME; Belouzard S; Pène V; Bonnafous P; Mesalam AA; Deloison G; Descamps V; Sahpaz S; Wychowski C; Lambert O; Brodin P; Duverlie G; Meuleman P; Rosenberg AR; Dubuisson J; Rouillé Y; Séron K
    J Virol; 2015 Oct; 89(19):10053-63. PubMed ID: 26202241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.
    Pietschmann T
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry.
    Hsu WC; Chang SP; Lin LC; Li CL; Richardson CD; Lin CC; Lin LT
    Antiviral Res; 2015 Jun; 118():139-47. PubMed ID: 25865056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methanolic Extract of
    Hung TC; Jassey A; Lin CJ; Liu CH; Lin CC; Yen MH; Lin LT
    Viruses; 2018 Nov; 10(12):. PubMed ID: 30486350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins.
    Li X; Li J; Feng Y; Cai H; Li YP; Peng T
    Antiviral Res; 2020 May; 177():104734. PubMed ID: 32057770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HCV entry as a new therapeutic target in chronic hepatitis C].
    Dabrowska MM; Panasiuk A; Flisiak R
    Pol Merkur Lekarski; 2009 Aug; 27(158):140-3. PubMed ID: 19856882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The science of direct-acting antiviral and host-targeted agent therapy.
    Pawlotsky JM
    Antivir Ther; 2012; 17(6 Pt B):1109-17. PubMed ID: 23188746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Progress in Examination and Treatment of Hepatitis C Virus].
    Suda G; Sakamoto N
    Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
    Fukasawa M
    Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
    Pár A
    Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes.
    Qian XJ; Zhang XL; Zhao P; Jin YS; Chen HS; Xu QQ; Ren H; Zhu SY; Tang HL; Zhu YZ; Qi ZT
    Sci Rep; 2016 Jun; 6():27268. PubMed ID: 27252043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
    Lee M; Yang J; Jo E; Lee JY; Kim HY; Bartenschlager R; Shin EC; Bae YS; Windisch MP
    Sci Rep; 2017 Mar; 7():44676. PubMed ID: 28333153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. News and challenges in the treatment of hepatitis C in liver transplantation.
    Coilly A; Roche B; Duclos-Vallée JC; Samuel D
    Liver Int; 2016 Jan; 36 Suppl 1():34-42. PubMed ID: 26725895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New perspectives in HCV therapy: entry inhibitors.
    Donia M; Cacopardo B; Libra M; Scalia G; McCubrey JA; Nicoletti F
    Recent Pat Antiinfect Drug Discov; 2010 Nov; 5(3):181-94. PubMed ID: 20497122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus.
    Chamoun-Emanuelli AM; Pécheur EI; Chen Z
    Antiviral Res; 2014 Sep; 109():141-8. PubMed ID: 25019406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
    Fukasawa M
    Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.